Skip to content

News archive

  • Association of Danish Pharmacies extends contract with NNIT for the operation and development of PharmaNet

    Association of Danish Pharmacies has chosen to continue their collaboration with NNIT for a further four years. NNIT will remain responsible for the operation and development of the PharmaNet system, which is the backbone of the daily customer service and financial management at more than 325 pharmacy units across Denmark. NNIT took over responsibility for the system in 2007.

  • NNIT and SAS Institute enters strategic collaboration on ISO IDMP

    Right now, Danish and European pharmaceutical companies are gearing up to comply with the ISO standards – designated IDMP – that come into force in the EU on 1 July 2016. The ISO IDMP standards require information from many areas of the pharmaceutical business, including regulatory affairs, research and development, manufacturing and distribution.

  • NNIT og Sitecore udvider samarbejdet

    Sitecore og NNIT har netop udvidet det eksisterende hostingsamarbejde til også at omfatte samlede leverancer af nye Sitecore-løsninger. Dermed kan NNIT fremover samlet levere alt fra rådgivning, implementering og vedligehold til drift samt support. Fokus er store danske virksomheder og organisationer.

  • Annual Report 2013: Controlled Growth

    NNIT's stable organic growth continued in 2013. Turnover increased by 9% to just over DKK 2.2 billion and the pre-tax result for primary operations was DKK 246 million, an increase of 14 % compared to the previous year. In addition, in the past year, NNIT increased its workforce and strengthened its market position via more global sourcing.

  • NNIT Årsrapport 2013: Kontrolleret vækst

    NNIT’s stabile organiske vækst fortsatte i 2013. Omsætningen steg med 9 pct. til godt 2,2 mia. kr., og resultatet af primær drift før skat blev 246 mio. kr., 14 pct. mere end året før. Derudover har NNIT i det forløbne år øget antallet af medarbejdere og styrket sin markedsposition via øget brug af global sourcing.

  • NNIT explores potential for initial public offering (IPO)

    NNIT informs that the company has been requested by Novo Nordisk to explore the potential for a listing on NASDAQ OMX Copenhagen. The aim is to explore the potential for an IPO and to evaluate whether a listing of NNIT would support the continued development and value creation of the company. A decision about the future ownership of NNIT will be made based on the outcome of the evaluation.

  • NNIT undersøger potentiale for børsnotering

    NNIT oplyser, at selskabet er blevet anmodet af Novo Nordisk om at undersøge mulighederne for en børsnotering af selskabet på NASDAQ OMX Copenhagen. Formålet er at afdække potentialet for en børsnotering af NNIT, og vurdere om dette vil kunne styrke selskabets fortsatte udvikling og værdiskabelse. En beslutning om det fremtidige ejerskab af NNIT vil blive baseret på de nærmere undersøgelser.

Show more